• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European Journal of Nuclear Medicine and Molecular Imaging >The management impact of (68)gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (Ga-68-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer
【24h】

The management impact of (68)gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (Ga-68-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer

机译：（68）镓 - Tris（羟基吡啶酮）前列腺特异性膜抗原（GA-68-THP-PSMA）PET-CT成像用于高风险和生物化学性复发前列腺癌的管理影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose To determine the impact on clinical management of patients with high-risk (HR) prostate cancer at diagnosis and patients with biochemical recurrence (BCR) using a new kit form of Ga-68-prostate-specific membrane antigen (PSMA), namely tris(hydroxypyridinone) (THP)-PSMA, with positron emission tomography-computed tomography (PET-CT). Methods One hundred eighteen consecutive patients (50 HR, 68 BCR) had management plans documented at a multidisciplinary meeting before Ga-68-THP-PSMA PET-CT. Patients underwent PET-CT scans 60-min post-injection of Ga-68-THP-PSMA (mean 159 +/- 21.2 MBq). Post-scan management plans, Gleason score, prostate-specific antigen (PSA) and PSA doubling time (PSAdt) were recorded. Results HR group: 12/50 (24%) patients had management changed (9 inter-modality, 3 intra-modality). Patients with PSA 20 mu g/L (3/24, 12.5%). Gleason scores > 8 were associated with detection of more nodal (4/16, 25% vs 5/31, 16.1%) and bone (2/16, 12.5% vs 2/31, 6.5%) metastases. BCR group: Clinical management changed in 23/68 (34%) patients (17 inter-modality, 6 intra-modality). Forty out of 68 (59%) scans were positive. Positivity rate increased with PSA level (PSA 8 (78.9% vs 51.2%). Conclusions Ga-68-THP-PSMA PET-CT influences clinical management in significant numbers of patient with HR prostate cancer pre-radical treatment and is associated with PSA. Management change also occurs in patients with BCR and is associated with PSA and Gleason score, despite lower scan positivity rates at low PSA levels < 0.5 mu g/L.
机译：目的是使用新的试剂盒形式的GA-68-前列腺特异性膜抗原（PSMA）的诊断和生化复发患者患者对高风险（HR）前列腺癌的临床管理的影响，即TRIS （羟基吡啶酮）（THP）-PSMA，具有正电子发射断层摄影 - 计算机断层扫描（PET-CT）。方法有一百十八名连续患者（50小时，68 BCR）在GA-68-THP-PSME PET-CT之前在多学科会议上进行了管理计划。患者接受了PET-CT扫描60分钟的幼术后注射了GA-68-THP-PSMA（平均159 +/- 21.2 MBQ）。记录了扫描后管理计划，Gleason评分，前列腺特异性抗原（PSA）和PSA倍增时间（PSADT）。结果HR组：12/50（24％）患者有管理改变（9次互别，3号内部）。 PSA20μg/ L（3/24,12.5％）的患者。 Glason评分> 8与检测更新（4/16,5 / 31,16.1％）和骨（2/16,12.5％Vs 2/31,6.5％）转移。 BCR组：临床管理发生在23/68（34％）患者（17个型号，6个内部）。在68（59％）的扫描中有四十（59％）是积极的。用PSA水平（PSA 8（78.9％Vs 51.2％）增加阳性率由于低PSA水平<0.5μg/升，BCR患者，BCR患者也发生了管理变化，并且与PSA和GLEASES评分相关。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号